True being limited to phase 1 would be the bigger limitation.

Another bigger impact might come by making regular researchers, lab workers, etc all more efficient by making data analysis more efficient or creating better tools. Possibly with less errors. That'd of course require big pharma to adopt them. We'll see on that point.